Search
Close this search box.

SECOND CASE IN NJ: Resident OF Englewood Hospitalized With Coronavirus


Health officials in New Jersey have announced a second positive case of coronavirus in the state.

That update came in a news conference held Thursday afternoon — the day after the first case was announced Wednesday.

A presumptive positive case means the sample tested positive at a state lab and has now been sent to the Centers for Disease Control and Prevention for confirmation.

Eight more people are under evaluation and could be tested, officials said.

The second presumptive positive case is a person from northern New Jersey and is hospitalized at Englewood Hospital in Englewood, New Jersey.

STAY UPDATED WITH BREAKING UPDATES FROM YWN VIA WHATSAPP – SIGN UP NOW Just click on this link, and you will be placed into a group.

He is hospitalized at Englewood Hospital in Englewood, New Jersey. The man is a resident of Engelwood, and has no known connection to the state’s first reported case, also in Bergen County, according to officials.

The first person in NJ is a 32-year-old man who is currently hospitalized in Bergen County and is stable, New Jersey Health Commissioner Judy Persichilli said.

The individual, who works in New York City, developed symptoms on March 1 and sought medical care late on March 2 at an urgent care clinic in Bergen County. He is said to be resting comfortably and doing well.

(YWN World Headquarters – NYC)



3 Responses

  1. https://www.unboundmedicine.com/medline/citation/32074550/full_citation

    Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Biosci Trends 2020

    Abstract
    The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People’s Republic of China for treatment of COVID-19 infection in larger populations in the future.

Leave a Reply


Popular Posts